Logo image of SUPN

SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Fundamental Analysis

USA - NASDAQ:SUPN - US8684591089 - Common Stock

46.13 USD
+1.33 (+2.97%)
Last: 9/18/2025, 8:26:13 PM
46.12 USD
-0.01 (-0.02%)
After Hours: 9/18/2025, 8:26:13 PM
Fundamental Rating

6

Taking everything into account, SUPN scores 6 out of 10 in our fundamental rating. SUPN was compared to 196 industry peers in the Pharmaceuticals industry. SUPN gets an excellent profitability rating and is at the same time showing great financial health properties. SUPN is not valued too expensively and it also shows a decent growth rate. These ratings would make SUPN suitable for quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year SUPN was profitable.
SUPN had a positive operating cash flow in the past year.
Each year in the past 5 years SUPN has been profitable.
In the past 5 years SUPN always reported a positive cash flow from operatings.
SUPN Yearly Net Income VS EBIT VS OCF VS FCFSUPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

1.2 Ratios

With an excellent Return On Assets value of 4.67%, SUPN belongs to the best of the industry, outperforming 87.24% of the companies in the same industry.
Looking at the Return On Equity, with a value of 6.06%, SUPN belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.
SUPN has a better Return On Invested Capital (4.10%) than 81.63% of its industry peers.
The Average Return On Invested Capital over the past 3 years for SUPN is significantly below the industry average of 15.28%.
The last Return On Invested Capital (4.10%) for SUPN is above the 3 year average (2.70%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 4.67%
ROE 6.06%
ROIC 4.1%
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
SUPN Yearly ROA, ROE, ROICSUPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

Looking at the Profit Margin, with a value of 9.70%, SUPN belongs to the top of the industry, outperforming 85.20% of the companies in the same industry.
In the last couple of years the Profit Margin of SUPN has declined.
Looking at the Operating Margin, with a value of 10.98%, SUPN belongs to the top of the industry, outperforming 84.18% of the companies in the same industry.
In the last couple of years the Operating Margin of SUPN has declined.
The Gross Margin of SUPN (89.87%) is better than 94.39% of its industry peers.
In the last couple of years the Gross Margin of SUPN has remained more or less at the same level.
Industry RankSector Rank
OM 10.98%
PM (TTM) 9.7%
GM 89.87%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
SUPN Yearly Profit, Operating, Gross MarginsSUPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SUPN is destroying value.
The number of shares outstanding for SUPN has been increased compared to 1 year ago.
SUPN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SUPN Yearly Shares OutstandingSUPN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SUPN Yearly Total Debt VS Total AssetsSUPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 6.35 indicates that SUPN is not in any danger for bankruptcy at the moment.
SUPN has a Altman-Z score of 6.35. This is amongst the best in the industry. SUPN outperforms 81.12% of its industry peers.
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.35
ROIC/WACC0.42
WACC9.8%
SUPN Yearly LT Debt VS Equity VS FCFSUPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 2.58 indicates that SUPN has no problem at all paying its short term obligations.
SUPN's Current ratio of 2.58 is in line compared to the rest of the industry. SUPN outperforms 47.45% of its industry peers.
SUPN has a Quick Ratio of 2.43. This indicates that SUPN is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.43, SUPN perfoms like the industry average, outperforming 51.02% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.58
Quick Ratio 2.43
SUPN Yearly Current Assets VS Current LiabilitesSUPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

SUPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.93%, which is quite impressive.
The Earnings Per Share has been growing slightly by 6.93% on average over the past years.
Looking at the last year, SUPN shows a small growth in Revenue. The Revenue has grown by 5.54% in the last year.
The Revenue has been growing by 11.00% on average over the past years. This is quite good.
EPS 1Y (TTM)50.93%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%16.88%
Revenue 1Y (TTM)5.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%-1.71%

3.2 Future

SUPN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.47% yearly.
The Revenue is expected to grow by 10.74% on average over the next years. This is quite good.
EPS Next Y-26.7%
EPS Next 2Y-13.28%
EPS Next 3Y11.32%
EPS Next 5Y18.47%
Revenue Next Year7.27%
Revenue Next 2Y12.58%
Revenue Next 3Y13%
Revenue Next 5Y10.74%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
SUPN Yearly Revenue VS EstimatesSUPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
SUPN Yearly EPS VS EstimatesSUPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6 8

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 14.15, the valuation of SUPN can be described as correct.
Based on the Price/Earnings ratio, SUPN is valued cheaper than 87.76% of the companies in the same industry.
SUPN is valuated rather cheaply when we compare the Price/Earnings ratio to 27.41, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 20.79, SUPN is valued on the expensive side.
SUPN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. SUPN is cheaper than 76.53% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.88. SUPN is around the same levels.
Industry RankSector Rank
PE 14.15
Fwd PE 20.79
SUPN Price Earnings VS Forward Price EarningsSUPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

88.78% of the companies in the same industry are more expensive than SUPN, based on the Enterprise Value to EBITDA ratio.
87.76% of the companies in the same industry are more expensive than SUPN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 13.92
EV/EBITDA 10.48
SUPN Per share dataSUPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The excellent profitability rating of SUPN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)2.04
EPS Next 2Y-13.28%
EPS Next 3Y11.32%

More info and screens

0

5. Dividend

5.1 Amount

SUPN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SUPERNUS PHARMACEUTICALS INC

NASDAQ:SUPN (9/18/2025, 8:26:13 PM)

After market: 46.12 -0.01 (-0.02%)

46.13

+1.33 (+2.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners108.97%
Inst Owner Change0.42%
Ins Owners4.08%
Ins Owner Change1.61%
Market Cap2.59B
Analysts80
Price Target44.68 (-3.14%)
Short Float %8.94%
Short Ratio5.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.64%
Min EPS beat(2)15.55%
Max EPS beat(2)87.73%
EPS beat(4)4
Avg EPS beat(4)84.8%
Min EPS beat(4)15.55%
Max EPS beat(4)158.74%
EPS beat(8)7
Avg EPS beat(8)81.53%
EPS beat(12)8
Avg EPS beat(12)38.3%
EPS beat(16)10
Avg EPS beat(16)29.24%
Revenue beat(2)1
Avg Revenue beat(2)2.29%
Min Revenue beat(2)-0.71%
Max Revenue beat(2)5.29%
Revenue beat(4)3
Avg Revenue beat(4)6.02%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)9.98%
Revenue beat(8)6
Avg Revenue beat(8)5.08%
Revenue beat(12)8
Avg Revenue beat(12)2.78%
Revenue beat(16)11
Avg Revenue beat(16)2.43%
PT rev (1m)8.96%
PT rev (3m)12.89%
EPS NQ rev (1m)-33.84%
EPS NQ rev (3m)-49.41%
EPS NY rev (1m)24.95%
EPS NY rev (3m)2.17%
Revenue NQ rev (1m)3.56%
Revenue NQ rev (3m)9.39%
Revenue NY rev (1m)7.57%
Revenue NY rev (3m)10.17%
Valuation
Industry RankSector Rank
PE 14.15
Fwd PE 20.79
P/S 3.89
P/FCF 13.92
P/OCF 13.83
P/B 2.43
P/tB 5.56
EV/EBITDA 10.48
EPS(TTM)3.26
EY7.07%
EPS(NY)2.22
Fwd EY4.81%
FCF(TTM)3.31
FCFY7.19%
OCF(TTM)3.34
OCFY7.23%
SpS11.86
BVpS18.97
TBVpS8.3
PEG (NY)N/A
PEG (5Y)2.04
Profitability
Industry RankSector Rank
ROA 4.67%
ROE 6.06%
ROCE 6.66%
ROIC 4.1%
ROICexc 7.83%
ROICexgc N/A
OM 10.98%
PM (TTM) 9.7%
GM 89.87%
FCFM 27.94%
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
ROICexc(3y)4.39%
ROICexc(5y)6.6%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.82%
ROCE(5y)7.36%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y11.61%
ROICexc growth 5Y-8.56%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
F-Score8
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 1.48%
Cap/Sales 0.18%
Interest Coverage 250
Cash Conversion 121.69%
Profit Quality 288.18%
Current Ratio 2.58
Quick Ratio 2.43
Altman-Z 6.35
F-Score8
WACC9.8%
ROIC/WACC0.42
Cap/Depr(3y)0.67%
Cap/Depr(5y)5.39%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.25%
Profit Quality(3y)2940.94%
Profit Quality(5y)1832.68%
High Growth Momentum
Growth
EPS 1Y (TTM)50.93%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%16.88%
EPS Next Y-26.7%
EPS Next 2Y-13.28%
EPS Next 3Y11.32%
EPS Next 5Y18.47%
Revenue 1Y (TTM)5.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%-1.71%
Revenue Next Year7.27%
Revenue Next 2Y12.58%
Revenue Next 3Y13%
Revenue Next 5Y10.74%
EBIT growth 1Y56.36%
EBIT growth 3Y-5.79%
EBIT growth 5Y-9.43%
EBIT Next Year3.46%
EBIT Next 3Y20.29%
EBIT Next 5Y21.99%
FCF growth 1Y161.05%
FCF growth 3Y11.03%
FCF growth 5Y4.05%
OCF growth 1Y160.89%
OCF growth 3Y10.6%
OCF growth 5Y3.74%